Expand the Application of Treg Therapies into a Clinical Reality

Accelerate the Translation of Modulator & Treg Cell Therapies to Redefine Immune Tolerance for Autoimmune, Inflammatory, & Neurodegenerative Diseases

With Nobel Prize recognition, clinical advances by Nektar Therapeutics and ORCA-T's potential as the first FDA-approved Treg cell therapy, Treg therapies are making waves.

At the 8th Treg-Directed Therapies Summit, Treg experts across leading academic institutions, trailblazing biotech and pharma, converge to overcome key challenges from cell targeting, Treg mechanisms of action and cytokine interactions, to indication selection, GMP and regulatory uncertainty, clinical trial design and established efficacy endpoints to push the boundaries of Treg application and clinical success.

Over three action-packed days, enjoy industry-tailored, data-packed presentations and interactive sessions led by pioneering companies unveiling their path to success to turn your innovations into a clinical reality.

Understanding and manipulating Tregs for the development of immunotherapy in autoimmune diseases, transplantation and cancer hold great promise for these patients. This summit is an ideal platform to learn and exchange the updated information and knowledge in the field.

Wanjun Chen, Senior Investigator, NIH

This meeting combined leading professionals in the Treg field and provided the opportunity to communicate on what is happening in the field and take key learnings back to the team.

Hong Jiang, Chief Scientific Officer, Avotres

I loved the content and particularly enjoyed that the presentations that covered Treg related therapies from early development to manufacturing and clinical development.

Zengli Guo, Associate Director, AstraZeneca

Explore the Full Event Guide

  • A Streamlined, Single-Track Agenda so You Can Catch Every Insightful Session Without Missing a Moment
  • A Refreshed Treg Biology Focus Day
  • 9 Hours of Dedicated Networking with the Global Treg Community
  • C-Suite Led Panel Discussions
  • New Data Presentations
  • A 75% New Speaker Faculty
66422 brochure image

More Than a Meeting

90+

Attendees from Across the Treg Community in One Place

25+

Speakers

7

C-Level
Speakers

35%

C-Suite Speaker Faculty

9+

Hours of Exclusive Networking Opportunities

8

New Companies Sharing New Insights

8+

Sessions Sharing New and Exciting Data

Official Partners

66422 brochure image

Attending Companies Include

Nektar Therapeutics
Quell Therapeutics
ThyTech
Cellenkos
Trex Bio
Mayo Clinic
Cue Biopharma
AstraZeneca
onsite image 4
Explore the Agenda

Hear the latest industry breakthroughs and gain exclusive insights during our packed agenda, interactive roundtables, and panel discussions.

onsite image 3
Partner With Us

Position yourself alongside other leading solution providers to ensure your brand is at the heart of biopharma deals.

im 3 (1)
Join Biopharma Experts

Be part of the hottest conversations with like-minded attendees spanning all stages of drug development and make critical connections during our dedicated networking sessions.